Table 1

Demographic and clinical details of patients treated with vigabatrin

PatientAgeSexEpilepsy duration (y)Seizure typesSyndrome
144M421,3Symptomatic temporal
256F102,3Symptomatic frontal
324F102,3Cryptogenic frontal
420F121,3Cryptogenic frontal
534M261,3Symptomatic temporal
655F541,3Symptomatic temporal
724M234Juvenile myoclonic
845M421Cryptogenic temporal
917F 3Paroxysmal kinesigenic  dystonia
1044F30Non-epileptic seizures
1112F 41,2Symptomatic temporal
1218M122,3Cryptogenic occipital
1318F171,3Cryptogenic temporal
1443M361,3Cryptogenic temporal
1534F231Cryptogenic temporal
1631F151,3Cryptogenic frontal
1741F391,3Cryptogenic temporal
1826F241,3Cryptogenic temporal
1967M 71,3Symptomatic frontal
2041M211,3Cryptogenic temporal
2132F244Idiopathic generalised
2226M241,3Symptomatic temporal
2343M284Idiopathic generalised
2448F321,3Cryptogenic temporal
2528F181,3Cryptogenic temporal
  • 1=Complex partial seizures; 2=simple partial seizures; 3=secondarily generalised tonic-clonic seizures; 4=primary generalised tonic-clonic seizures; 5=absences.